(RSV) is a common cause of lower respiratory tract infection (LRTI) and is responsible for a high burden of hospital admission and mortality in children. RSV–LRTI is also associated with long-term ...

Respiratory virus season is quickly approaching, meaning we will start to see cold, flu, COVID, and RSV in our community. The ...

Global Respiratory Syncytial Virus Therapeutics Market was valued at approximately USD 5.88 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 12.82% over the forecast ...

With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...

The following is a summary of “Respiratory viral infections from 2015 to 2022 in the HIVE cohort of American households: Incidence, illness characteristics, and seasonality,” published in the August ...

GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The ...

Fall brings cooler days and more time indoors. This makes it easier for viruses like influenza (flu), COVID-19 and ...

Moderna is deprioritizing certain parts of its pipeline, which involves pausing work on some products and scrapping others.

Forecasts from the US Centers for Disease Control and Prevention suggest that this respiratory disease season will be similar to last year’s — which brought ... ahead of the respiratory virus season.” ...

A vaccine to protect babies and older adults against a common but potentially dangerous respiratory infection is set to be rolled out on the Isle of Man. Respiratory syncytial virus (RSV ...

“Make a plan now for you and your family to get both updated flu and COVID vaccines this fall, ahead of the respiratory virus season ... dose of flu vaccine each year. But some children ...